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This study extends earlier reports regarding the in vitro efficacies of the 1,4-di-N-oxide quinoxaline deriv-
atives against Mycobacterium tuberculosis and has led to the discovery of a derivative with in vivo efficacy in the
mouse model of tuberculosis. Quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives were tested in vitro against
a broad panel of single-drug-resistant M. tuberculosis strains. The susceptibilities of these strains to some
compounds were comparable to those of strain H37Rv, as indicated by the ratios of MICs for resistant and
nonresistant strains, supporting the premise that 1,4-di-N-oxide quinoxaline derivatives have a novel mode of
action unrelated to those of the currently used antitubercular drugs. Specific derivatives were further evaluated
in a series of in vivo assays, including evaluations of the maximum tolerated doses, the levels of oral
bioavailability, and the efficacies in a low-dose aerosol model of tuberculosis in mice. One compound, ethyl
7-chloro-3-methylquinoxaline-2-carboxylate 1,4-dioxide, was found to be (i) active in reducing CFU counts in
both the lungs and spleens of infected mice following oral administration, (ii) active against PA-824-resistant
Mycobacterium bovis, indicating that the pathway of bioreduction/activation is different from that of PA-824 (a
bioreduced nitroimidazole that is in clinical trials), and (iii) very active against nonreplicating bacteria
adapted to low-oxygen conditions. These data indicate that 1,4-di-N-oxide quinoxalines hold promise for the
treatment of tuberculosis.
The high number of multidrug-resistant Mycobacterium tu-
berculosis strains circulating worldwide has increased concern
that tuberculosis (TB) may once again become an incurable
disease and has emphasized the need for new drugs to treat
this infection. Over the last few years, extensively drug-resis-
tant TB, defined as TB caused by M. tuberculosis strains resis-
tant to isoniazid (INH), rifampin, any fluoroquinolone, and
one of the injectable drugs amikacin, kanamycin, and capreo-
mycin, has become a major concern for TB treatment and
control in the global setting (2, 7, 9, 11, 12, 16, 19, 28, 31). In
addition, strains with resistance to all of the major clinically
used antitubercular drugs are known (21), thus answering the
question posed by Dye and Espinal, “Will tuberculosis become
resistant to all antibiotics?” (8).
Our antitubercular research group has previously published
several papers in which the synthesis and primary biological
valuation of a large number of quinoxaline and quinoxaline
1,4-di-N-oxide derivatives were described (14, 22, 24–27, 32).
In this context, different quinoxaline-2-carboxylate 1,4-dioxide
derivatives were synthesized and evaluated as anti-M. tubercu-
losis agents (15). Some of them showed good in vitro param-
eters in a cytotoxicity assay and in an M. tuberculosis-infected
macrophage model (Table 1). In this report, we detail the in
vitro activities and in vivo efficacies of quinoxaline-2-carboxy-
late 1,4-di-N-oxide derivatives.
(Portions of these data were presented in abstract form at
the Gordon Conference on Tuberculosis and Drug Develop-
ment, Oxford, United Kingdom, August 2007, and the 38th
Union World Conference on Lung Health of the International
Union against Tuberculosis and Lung Disease, Cape Town,
South Africa, November 2007.)
MATERIALS AND METHODS
Compound synthesis. The quinoxaline derivatives used in this study were
prepared by procedures described in the literature (15, 26) by the reaction of the
appropriate benzofuroxan with the corresponding -ketoester. The structural
properties of the compounds were confirmed by nuclear magnetic resonance,
mass spectrometry, and infrared analyses, and the purity was established by
elemental analyses. The compounds described in the present work have demon-
strated activity in previous assays (15): a MIC and cytotoxicity assay and an assay
of activity against M. tuberculosis growing in macrophages. A list of the com-
pounds and their structures and biological activities is presented in Table 1.
Determination of minimum bactericidal concentrations (MBCs) and MICs
for single-drug-resistant strains ofM. tuberculosis. Compounds were dissolved in
dimethyl sulfoxide and diluted in test media to the desired concentrations, with
the final dimethyl sulfoxide concentration kept below 0.625%. MICs for a min-
imum of three strains of drug-resistant M. tuberculosis (each strain resistant to
a single TB drug) were determined by the microplate Alamar Blue assay
(MABA) (10).
The MBCs for the M. tuberculosis H37Rv strain and the other strains tested
were then determined by subculturing the strains onto drug-free solid medium
and enumerating CFU after exposure for 5 days at 37°C in Middlebrook 7H9
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medium supplemented with drug concentrations equivalent to and higher than
the previously determined MICs for the respective strains. The MBC was the
lowest concentration of the drug that killed more than 99.9% of the bacterial
population present when the drug was added.
Potential for cross-resistance with PA-824. PA-824 is a nitroimidazole agent in
clinical trials for treating TB. Mycobacterium bovis strains resistant to PA-824,
created using Tn5367 mutagenesis (4), were obtained from Lacy Daniels (Texas
A&M College of Pharmacy, Kingsville, TX). MICs were determined by broth
microdilution using the MABA. PA-824 was obtained from the Global Alliance
for Tuberculosis Drug Development (New York, NY).
Maximum tolerated dose (MTD) and oral bioavailability. All experiments
using mice were approved by the Animal Care and Use Committee at Colorado
State University (approval no. 06-221A-02; expiration date, 17 October 2008)
and under Animal Welfare Assurance number A3572-01. Single doses of drugs
at 100, 300, or 1,000 mg/kg of body weight were administered (by gavage) to
three C57BL/6 female mice per dose. Mice were observed postadministration at
4 and 6 h and then twice daily for the duration of the study (1 week). The oral
bioavailability was determined by bioassays as described previously (13).
Rapid in vivo screen. Eight- to 10-week-old female specific-pathogen-free
C57BL/6-Ifngtm1ts mice (gamma interferon gene knockout [GKO] mice) were
purchased from Jackson Laboratories, Bar Harbor, ME (6). Mice were infected
via low-dose aerosol exposure to M. tuberculosis Erdman by using a Middlebrook
aerosol generation device (Glas-Col Inc., Terre Haute, IN), and the rapid screen-
ing model was carried out as described previously (18). One day postinfection,
three mice were sacrificed to verify the uptake of 50 to 100 CFU of bacteria per
mouse. Negative control mice remained untreated. An INH-treated control
group, receiving the drug via oral gavage at 25 mg/kg/day, was included in each
study. Each treatment group consisted of five mice. Treatment was started 18
days postinfection and continued for nine consecutive days. Five infected mice
were killed at the start of treatment as pretreatment controls. Drugs were
administered daily by oral gavage using 0.5% methyl cellulose (200-l volumes).
Dose-response analysis in the rapid in vivo screen. The in vivo activity of
compound 8 (Tuberculosis Antimicrobial Acquisition and Coordinating Facility
[TAACF] no. 151985) was examined in the rapid screening model to repeat the
efficacy testing and to estimate the minimal effective dose. Doses of 25, 100, and
300 mg/kg were tested using the same methods as those in the initial in vivo test.
Statistical analysis. The viable counts were converted to logarithms, which
were then evaluated by a one-way analysis of variance followed by a multiple-
comparison analysis of variance using a one-way Tukey test (in the SigmaStat
software program). Differences were considered significant at the 95% level of
confidence.
Activity against nonreplicating persistent M. tuberculosis. The activity of com-
pound 8 against nonreplicating M. tuberculosis was determined by measuring the
activity against M. tuberculosis bacteria adapted to a low-oxygen environment
under anaerobic conditions (3). This low-oxygen-recovery assay (LORA) quan-
tifies antibacterial activity by measuring the ability of an M. tuberculosis recom-
binant strain, containing a plasmid with an acetamidase promoter driving a
bacterial luciferase gene, to produce a luminescent signal when placed back into
an environment with ambient oxygen.
RESULTS AND DISCUSSION
The most potent compounds from our previous studies were
subjected to the following set of tests: determination of (i) the
MICs for different single-drug-resistant strains of M. tubercu-
losis, (ii) the MBCs, (iii) the activities against nonreplicating
bacteria, (iv) the MTDs, (v) the levels of oral bioavailability,
and (vi) the in vivo efficacies.
Table 2 shows the MICs obtained for single-drug-resistant
strains of M. tuberculosis, including those resistant to INH, ri-
fampin, thiacetazone, ethambutol (EMB), ciprofloxacin (CIP),
kanamycin (KAM), ethionamide, and p-aminosalicylic acid. In
general, all the compounds showed good MICs for resistant
strains; MICs ranged between 0.1 and 6.25 g/ml, with the ex-
ception of that of 3,7-dimethylquinoxaline-2-carboxylate 1,4-di-N-
oxide (compound 2), a drug which showed poor activity against
EMB-resistant and KAM-resistant strains, with MICs of 25 g/
ml. The susceptibilities of resistant strains can be considered com-
parable to those of H37Rv, as indicated by the ratios of MICs for
resistant and nonresistant M. tuberculosis strains (calculations not
shown). This finding suggests that there is minimal if any cross-
resistance with the current anti-TB drugs, thereby supporting the
notion of a novel mechanism of action. These results are prom-
TABLE 1. Structures of the quinoxaline derivatives and previously reported in vitro activities against M. tuberculosisa
Compound TAACF no. R7 R6 R2 MIC (g/ml) SI (L 2)b EC90/MIC (L 3)c
1 148141 CH3 CH3 CH3 3.13 20 0.52
2 151991 CH3 H CH3 1.56 40.06 1.24
3 149515 CH3 CH3 CH2CH3 6.25 10 0.46
4 151992 CH3 H CH2CH3 1.56 40.06 1.40
5 150564 H H CH2CH3 1.56 30.13 0.56
6 115347 Cl Cl CH2CH3 0.20 20 3.15
7 151985 Cl H CH2CH3 0.20 50 2.30
8 149513 Cl Cl (CH2)2OCH3 0.39 11.54 4.00
9 153731 CH3 H CH2Ph 0.39 143.7 2.90
10 150565 H H CH2Ph 0.10 470 1.50
11 149514 Cl Cl CH2Ph 0.20 29 14.35
12 153293 Cl H CH2Ph 0.10 76.9 0.01
a Data are from reference 15.
b The SI is the selectivity index calculated as the concentration inhibiting the growth of Vero cells in culture by 50% following 72 h of exposure (assessed using the
CellTiter 96 nonradioactive cell proliferation assay reagent from Promega) divided by the MIC. L 2, assay level 2 according to the TAACF assay program.
c EC90/MIC is a measure of the activity against intracellular M. tuberculosis taken up by mouse bone marrow macrophages, calculated as the 90% effective
concentration (EC90), or the concentration required to inhibit the growth of intracellular M. tuberculosis by 90%, divided by the MIC. L 3, assay level 3 according to
the TAACF assay program.
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ising for the development of new effective compounds against the
growing number of drug-resistant strains. The quinoxaline-2-car-
boxylate derivative with a benzyl group in the carboxylate (com-
pound 10) was the most active compound, with MICs of 0.4g/ml
or less for the resistant strains.
Compound 7 is likely activated via bioreduction in bacteria,
similar to the reduction observed for other N-oxides (29). Since
PA-824, a nitroimidazole in clinical trials for treating TB, is
bioreduced into an active intermediate (4, 5, 20), we tested the
activity of compound 7 against an isogenic set of M. bovis
strains with defined resistance to PA-824. PA-824 is biore-
duced into an active form by a pathway involving the deazafla-
vin F420 cofactor-dependent glucose dehydrogenase (Fdg1)
and other cellular factors, including molybdopterin, a cofactor
for many oxidoreductase enzymes. Thus, the loss of function of
Fdg1 or the loss of the ability to synthesize the F420 cofactor
leads to resistance to PA-824 (Table 3). Compound 7 was
active against all PA-824-resistant M. bovis strains tested, thus
showing the lack of cross-resistance and supporting the evi-
dence for a different pathway of drug activation. Niclosamide
(an anthelmintic agent that shows poor absorption from the
host intestine) was included as another control compound that
is structurally different from PA-824 and activated by a differ-
ent pathway (1).
Compound 7 was also tested under aerobic and anaerobic
(LORA) conditions for activity against M. tuberculosis strain
H37Rv containing the luciferase reporter. Compound 7 was active
under aerobic growth conditions (MIC  0.24 g/ml) and under
anaerobic conditions (LORA MIC  0.42 g/ml). The corre-
sponding values for PA-824 and niclosamide were as follows:
MICs under aerobic growth conditions, 0.10 and 0.28 g/ml, re-
spectively, and LORA MICs, 1.4 and 0.32 g/ml, respectively.
Activity against nonreplicating bacteria is another unique prop-
erty of quinoxaline 1,4-di-N-oxides. Although the idea is specula-
tive, activity targeting nonreplicating bacteria may translate into
faster sterilization of infected tissues, and we are in the process of
testing this possibility in animal models. The long continuation
phase for the treatment of TB is believed to be due in part to the
presence of nonreplicating organisms that persist even in the
presence of antitubercular drugs. PA-824 is an experimental ni-
troimidazole that is in phase I clinical trials. PA-824 is bioreduced
by M. tuberculosis into an active component. Niclosamide is an-
other bioreduced drug that is active in the LORA. Compound 7
TABLE 2. MICs for strains of single-drug-resistant M. tuberculosis
Compound
MIC (g/ml)a for:
H37Rv INH-R RIF-R TAC-R EMB-R CIP-R KAM-R ETA-R PAS-R
1 3.13 3.13 3.13 1.56 1.56 3.13 3.13 3.13 3.13
2 3.13 6.25 3.13 1.56 25 6.25 25 3.13 3.13
3 3.13 6.25 3.13 3.13 3.13 12.5 3.13 6.25 NDb
4 3.13 ND 3.13 0.39 ND 6.25 ND 6.25 3.13
5 1.56 1.56 1.56 ND 1.56 3.13 1.56 ND ND
6 0.2 0.39 0.2 ND 0.2 0.2 0.1 ND ND
7 0.20 0.39 0.39 ND 0.39 0.78 0.39 ND ND
8 0.2 0.2 0.2 0.39 ND 0.39 ND 0.78 0.78
9 0.39 ND 0.39 0.39 ND 0.39 ND 1.56 0.78
10 0.2 0.2 0.2 0.2 ND 0.1 ND 0.4 0.2
11 0.39 1.56 0.39 0.78 0.78 0.39 0.39 0.78 ND
a INH-R, INH-resistant strain; RIF-R, rifampin-resistant strain; TAC-R, thiacetazone-resistant strain; EMB-R, EMB-resistant strain; CIP-R, ciprofloxacin-resistant
strain; KAM-R, KAM-resistant strain; ETA-R, ethionamide-resistant strain; PAS-R, p-aminosalicylic acid-resistant strain.
b ND, not determined.
TABLE 3. In vitro activities against susceptible and genetically defined PA-824-resistant mycobacteria
Strain (characteristic, function, or
alternative designation of
relevant gene)
MIC (M) of:
PA-824
Compound 7
Niclosamide
BCG WTa 0.12 0.50 3.13
fgd (F420 dependent) 128 0.50 1.61
moaA (molybdopterin synthesis) 128 0.38 1.86
fbiC (F420 synthesis) 128 0.71 1.57
moaD (molybdopterin synthesis) 128 0.55 1.90
pil 8b (Rv2627) 128 0.72 1.87
a BCG WT, wild-type M. bovis strain BCG Montreal; MICs for this strain were measured by the MABA, as were those for all other M. bovis strains.
b The precise function of pil 8 (Rv2627) is unknown.
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was slightly more active than PA-824 in the LORA on a molar
basis (1.5 M versus 4.85 M).
The MBCs of select compounds for H37Rv, along with the
MICs, were determined using the MABA (10). The MIC of
compound 7 tested as 0.6 g/ml in this assay, and the MBC was
2.5 g/ml (MBC/MIC ratio  4.2). The MIC of compound 6
was 0.2 g/ml, with an MBC of 3.13 g/ml (MBC/MIC ratio 
15.7), and the MIC of compound 10 was 0.39 g/ml, with an
MBC of 6.25 g/ml (MBC/MIC ratio  16.0). A compound
is generally considered to be bactericidal if the ratio of the
MBC to the MIC is4 (30), so the ratios for these compounds
against H37Rv indicated bacteriostatic rather than bactericidal
activity by this definition. However, bactericidal activity in vivo
is determined by peak levels in blood and tissues and exposure
times following oral administration. The in vivo peak levels of
compound 7 in serum reached 5 to 8 g/ml 15 to 30 min
following the administration of 100- to 200-mg/kg doses, as
determined by bioassays, and bactericidal activity was observed
in vivo (see below for more on in vivo efficacy).
Selected compounds 6 to 12 were evaluated in in vivo assays,
including tests for efficacy in the mouse model of TB infection.
The MTD of each compound was determined by using an
escalating single dose of the drug given to mice by oral gavage.
No acute adverse effects, reactions, or toxicity were observed at
oral doses of up to 1,000 mg/kg (the highest dose tested).
Subsequent in vivo evaluations of the efficacies of compounds
6 to 12 were done with doses of 300 mg/kg administered via
oral gavage to infected GKO C57BL/6 mice (18). Six of the
seven compounds were found to be inactive in that they did not
effectively reduce the bacterial numbers in the lungs and
spleens with respect to those in the untreated controls (Table
4). While we have not definitively determined the reason for
the lack of in vivo efficacy of compounds 6 and 8 to 12, it
appears that the lack of activity of compound 10 may be due to
extensive serum binding, since the MIC is reduced 200-fold in
the presence of serum. Likewise, the lack of efficacy of com-
pound 6 appears to be due to a short in vivo half-life, based on
the results of preliminary studies. The lack of activity was not
due to the potency of M. tuberculosis strain Erdman, as all of
the compounds were active against this strain (Table 4).
However, the ethyl 7-chloroquinoxaline derivative (com-
pound 7) afforded significant reductions of 3.2 and 2.62 log10
CFU in lungs and spleens, respectively. Generally, compounds
are considered to be active if they yield at least a 0.75-log10
reduction in bacterial counts compared to day 24 counts. The
protection shown by compound 7 is similar to that afforded by
clinically available compounds and other compounds classified
as very active (17). INH reduced the numbers of CFU by 3.10
and 4.17 log units in the same experiment. Since the majority
of compounds showing good in vitro activity do not show in
vivo efficacy in mice (23), the in vivo activity of ethyl 7-chloro-
3-methylquinoxaline-2-carboxylate 1,4-di-N-oxide is promising.
Bactericidal activity of compound 7 was observed, since the
final lung CFU count following 9 days of treatment was below
the starting lung CFU count on day 15, the day therapy was
initiated (6.81 log CFU untreated lung, compared to 4.55 log
CFU following 9 days of treatment) (Table 4). Similar evi-
dence for bactericidal activity was obtained from the spleen
data, with an initial count of 5.37 log CFU untreated spleen
compared to 3.95 log CFU following 9 days of treatment
(Table 4).
In a second experiment (Table 5), the dose-response rela-
tionship for compound 7 in vivo was determined using the
GKO mouse model and doses of 25, 100, and 300 mg/kg (Table
5). Compound 7 was weakly active in the lung and spleen at a
dose of 25 mg/kg (CFU readings for tissues from treated mice
on day 24 were lower than those for tissues from the untreated
controls on day 24, but the activity appeared to be bacterio-
static). At 100 and 300 mg/kg (P, 0.001 by a one-way analysis
of variance followed by a multiple-comparison analysis of vari-
ance using a one-way Tukey test in the SigmaStat software
TABLE 4. Evaluation of in vivo efficacies in the GKO mouse modela
Treatment (dose
mg/kg or time
point)
TAACF no.
(MIC)b Organ
Log CFU/
organ (SD)
Log CFU
decrease
vs control
None (day 15) Lung 6.81 (	0.09)
Spleen 5.37 (	0.18)
None (day 24) Lung 7.57 (	0.11)
Spleen 6.57 (	0.17)
INH (25) Lung 4.47 (	0.12) 3.10
Spleen 2.20 (	0.45) 4.37
Compound 6
(300)
115347 (0.39) Lung 7.64 
0.06
Spleen 6.75 
0.18
Compound 7
(300)
151985 (0.78) Lung 4.55 (	0.23) 3.02
Spleen 3.95 (	0.10) 2.62
Compound 8
(300)
149513 (0.39) Lung 8.73 
0.68
Spleen 7.18 
0.47
Compound 9
(300)
153731 (0.78) Lung 7.17 0.4
Spleen 6.63 
0.016
Compound 10
(300)
150565 (0.10) Lung 7.41 0.16
Spleen 6.96 
0.38
Compound 11
(300)
149514 (0.10) Lung 8.07 
0.03
Spleen 7.17 
0.46
Compound 12
(300)
153293 (0.10) Lung 7.21 0.36
Spleen 6.62 
0.05
a Results from experiment 1 are shown.
b The MICs for M. tuberculosis strain Erdman (used in the in vivo efficacy
testing) were determined for all compounds selected for in vivo efficacy testing
and are given in parentheses.
TABLE 5. Dose-response data for compound 7 (TAACF 151985)
in the GKO mouse model
Treatment (dose
mg/kg or time
point)
Organ Log CFU/organ (SD)
Log CFU
decrease
vs control
Comment
None (day 15) Lung 6.62 (	0.14) NAa Normal
Spleen 4.42 (	0.52) NA Normal
None (day 24) Lung 7.76 (	0.10) NA Normal
Spleen 6.86 (	0.16) NA Normal
INH (25) Lung 4.43 (	0.06) 3.33 Normal
Spleen 1.82 (	0.31) 5.04 1 Mouse
without CFU
TAACF 151985
(25)
Lung 6.77 (	0.03) 0.99 Normal
Spleen 5.25 (	0.48) 1.61 Normal
TAACF 151985
(100)
Lung 5.73 (	0.05) 2.03 Normal
Spleen 4.14 (	0.22) 2.72 Normal
TAACF 151985
(300)
Lung 2.18 (	1.30) 5.58 Toxicityb
Spleen 1.35 (	0.65) 5.51 Toxicityb
a NA, not applicable.
b Data were obtained from only two mice. Three deaths occurred due to
apparent drug toxicity. Only one surviving mouse had CFU; the other mouse was
culture negative. Therapy stopped at 7 days. Mice were slightly lethargic, with a
hunched posture.
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program), compound 7 appeared to be bactericidal, since the
numbers of CFU recovered from both the lungs and spleens
were well below the CFU levels observed on day 15 (Table 5),
except for the spleens from the 100-mg/kg-dose group, in
which the mean number of CFU was reduced by only 0.28 logs,
which was not significant. Activity at a dose of 300 mg/kg was
striking in that it lowered the numbers of CFU by 5.58 and 5.51
logs, respectively, in the lungs and spleens. Although no clear
toxicity was apparent in the single-dose MTD test and in the
first in vivo experiment, some toxicity was observed in the
second dose-response experiment; three mice in the 300-mg/kg
group died during treatment, which was truncated to 7 days
instead of the usual 9 days. No CFU were recovered from the
lung and spleen of one of the surviving mice dosed at 300
mg/kg when the entire organs were plated for CFU enumera-
tion. Although it appears that multiple dosing at 300 mg/kg
may result in some toxicity in infected animals, data collected
to date on this series (quinoxaline-2-carboxylate 1,4-di-N-oxide
derivatives) indicate that both in vitro (cytotoxicity) and in vivo
toxicity can be separated from the antitubercular activity, as
determined by plotting MICs versus 50% inhibitory concentra-
tions for over 100 analogs, wherein no correlation was ob-
served. Although the MTD is high (1,000 mg/kg for normal
mice), we have observed that some compounds can show tox-
icity in infected GKO mice at lower levels, due likely to the
added stress of disease. Thus, 300 mg/kg may be on the bor-
derline for tolerability in GKO infected mice and may there-
fore show toxicity in some experiments. Experiments with nor-
mal C57BL/6 mice and longer treatment times are being
scheduled.
In conclusion, an extended evaluation of the in vitro and
in vivo antimycobacterial activities of quinoxaline 1,4-di-N-
oxide derivatives was performed. Most of these compounds
displayed good inhibitory activity against resistant strains,
and only compound 2 was associated with apparent cross-
resistance in EMB-resistant and KAM-resistant strains, al-
though we have not yet confirmed these data. Compound 7
was the only analog active in vivo. This activity was clearly
due to adequate oral bioavailability and levels in the blood
(measured at 3, 6, and 9 g/ml for the 25-, 100-, and 300-
mg/kg doses, respectively) and to a terminal elimination
half-life of 4 to 8 h (unpublished data). Finally, we did
detect bactericidal activity when we tested the sera of ani-
mals dosed orally with 200 mg of compound 7/kg and bled at
30 min. Sera diluted twofold killed 2.51 logs, and when
diluted fourfold, they still killed 1.15 logs after 7 days of
incubation. Thus, compound 7 has all of the necessary char-
acteristics of a validated lead that can serve as the starting
point for more advancement in medicinal chemical and pre-
clinical development.
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